Form 4: NewAmsterdam Pharma CEO Acquires 15,000 Warrants
SEC Form 4 Filing
Michael H. Davidson, CEO of NewAmsterdam Pharma Co N.V., reports the acquisition of 15,000 warrants exercisable for ordinary shares.
Summary
- Michael H. Davidson, the CEO of NewAmsterdam Pharma Co N.V., filed a Form 4 with the SEC.
- The filing reports a transaction on October 9, 2024, where Davidson acquired 15,000 warrants.
- These warrants have an exercise price of $11.50 and are exercisable for ordinary shares.
- The warrants were originally granted on December 22, 2022, and expire on November 23, 2027.
- Following the reported transaction, Davidson directly owns 85,000 warrants.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a change in the beneficial ownership of securities by a company insider.
Stakeholder Impact
- The acquisition of warrants by the CEO could be viewed positively by shareholders as it aligns management's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 12/22/2022 | Original grant date of the warrants |
| 10/09/2024 | Date of warrant acquisition by Michael H. Davidson |
| 10/11/2024 | Date of Form 4 filing |
| 11/23/2027 | Expiration date of the warrants |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.